• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.

作者信息

van de Donk Niels W C J, Wittebol Shulamit, Minnema Monique C, Lokhorst Henk M

出版信息

Br J Haematol. 2010 Jan;148(2):335-7. doi: 10.1111/j.1365-2141.2009.07931.x.

DOI:10.1111/j.1365-2141.2009.07931.x
PMID:20085583
Abstract
摘要

相似文献

1
Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.
Br J Haematol. 2010 Jan;148(2):335-7. doi: 10.1111/j.1365-2141.2009.07931.x.
2
Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients.来那度胺（瑞复美）联合环磷酰胺和地塞米松（RCD）方案，对于骨髓瘤患者而言是一种有效且耐受性良好的治疗方案。
Br J Haematol. 2007 May;137(3):268-9. doi: 10.1111/j.1365-2141.2007.06538.x.
3
Treatment with lenalidomide (Revlimid®), cyclophosphamide (Endoxan®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study.来那度胺（瑞复美®）、环磷酰胺（环磷酰胺®）和泼尼松（REP）治疗复发/难治性多发性骨髓瘤患者：单中心回顾性研究结果
Acta Clin Belg. 2014 Apr;69(2):98-103. doi: 10.1179/0001551214Z.00000000030. Epub 2014 Mar 4.
4
Lenalidomide and its role in the management of multiple myeloma.来那度胺及其在多发性骨髓瘤治疗中的作用。
Expert Rev Anticancer Ther. 2008 Jun;8(6):865-74. doi: 10.1586/14737140.8.6.865.
5
DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.DTPACE：一种用于既往接受过治疗的骨髓瘤患者的、含沙利度胺的有效新型联合化疗方案。
J Clin Oncol. 2003 Jul 15;21(14):2732-9. doi: 10.1200/JCO.2003.01.055.
6
Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.口服环磷酰胺、泼尼松和来那度胺治疗复发难治性多发性骨髓瘤患者的I-II期试验
Br J Haematol. 2015 Jan;168(1):46-54. doi: 10.1111/bjh.13100. Epub 2014 Aug 22.
7
Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.先前的沙利度胺治疗可能不会影响复发或难治性多发性骨髓瘤患者对来那度胺的反应和结果。
Eur J Cancer. 2011 Apr;47(6):814-8. doi: 10.1016/j.ejca.2010.12.026. Epub 2011 Feb 18.
8
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.美法仑、泼尼松和来那度胺治疗新诊断的骨髓瘤：来自GIMEMA（意大利多发性骨髓瘤网络）的报告
J Clin Oncol. 2007 Oct 1;25(28):4459-65. doi: 10.1200/JCO.2007.12.3463. Epub 2007 Sep 4.
9
Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.低剂量沙利度胺联合口服每周一次环磷酰胺和脉冲式地塞米松，对于复发和难治性多发性骨髓瘤患者是一种耐受性良好且有效的治疗方案。
Br J Haematol. 2005 Jun;129(6):763-70. doi: 10.1111/j.1365-2141.2005.05521.x.
10
Treatment of multiple myeloma: 2009 update.多发性骨髓瘤的治疗：2009年更新
Prescrire Int. 2009 Dec;18(104):263-6.

引用本文的文献

1
Management of Relapsed-Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice.先进疗法时代复发难治性多发性骨髓瘤的管理：基于证据的常规临床实践建议
Cancers (Basel). 2023 Apr 5;15(7):2160. doi: 10.3390/cancers15072160.
2
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma.新诊断多发性骨髓瘤患者基于来那度胺的治疗的临床管理。
Ann Hematol. 2020 Aug;99(8):1709-1725. doi: 10.1007/s00277-020-04023-4. Epub 2020 Apr 16.
3
Management of multiple myeloma in the relapsed/refractory patient.
复发性/难治性多发性骨髓瘤的治疗。
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):508-517. doi: 10.1182/asheducation-2017.1.508.
4
A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma.卡非佐米在复发或难治性多发性骨髓瘤治疗中作用的临床进展
Ther Adv Hematol. 2016 Dec;7(6):330-344. doi: 10.1177/2040620716667275. Epub 2016 Sep 13.
5
Treatment of relapsed and refractory multiple myeloma.复发难治性多发性骨髓瘤的治疗
Haematologica. 2016 Apr;101(4):396-406. doi: 10.3324/haematol.2015.129189.
6
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.复发多发性骨髓瘤的治疗：国际骨髓瘤工作组的建议。
Leukemia. 2016 May;30(5):1005-17. doi: 10.1038/leu.2015.356. Epub 2015 Dec 29.
7
Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.来那度胺与大剂量美法仑联合自体干细胞移植治疗复发性骨髓瘤的I/II期试验
Leukemia. 2015 Sep;29(9):1945-8. doi: 10.1038/leu.2015.54. Epub 2015 Feb 27.
8
Novel agents and new therapeutic approaches for treatment of multiple myeloma.用于治疗多发性骨髓瘤的新型药物和新治疗方法。
World J Methodol. 2014 Jun 26;4(2):73-90. doi: 10.5662/wjm.v4.i2.73.
9
Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma.克拉霉素可克服多发性骨髓瘤对来那度胺和地塞米松的耐药性。
Am J Hematol. 2014 Aug;89(8):E116-20. doi: 10.1002/ajh.23733. Epub 2014 Apr 26.
10
Successful use of cyclophosphamide as an add-on therapy for multiple myeloma patients with acquired resistance to bortezomib or lenalidomide.环磷酰胺作为硼替佐米或来那度胺获得性耐药的多发性骨髓瘤患者的附加治疗药物的成功应用。
Case Rep Hematol. 2013;2013:651902. doi: 10.1155/2013/651902. Epub 2013 Mar 28.